Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-hodgkin lymphoma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 6, 2015, Pages 335-340

  Ayala, Ernesto ^a,b   Figueroa, Javier ^a   Perkins, Janelle ^a   Kim, Jongphil ^a   Yue, Binglin ^a   Riches, Marcie ^a,b   Nishihori, Taiga ^a,b   Locke, Frederick ^a,b   Anasetti, Claudio ^a,b   Kharfan Dabaja, Mohamed A ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Allogeneic hematopoietic cell transplantation; Intravenous fludarabine and busulfan; Myeloablative conditioning; Non hodgkin lymphoma; Non relapse mortality

Indexed keywords

BUSULFAN; FLUDARABINE; LORAZEPAM; METHOTREXATE; MYCOPHENOLATE MOFETIL; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; URSODEOXYCHOLIC ACID; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; MYELOABLATIVE AGENT; VIDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REDUCTION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; LIVER DYSFUNCTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEIZURE; TREATMENT RESPONSE; ADVERSE EFFECTS; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; DISEASE FREE SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; PROCEDURES; RECURRENT DISEASE; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTINEOPLASTIC AGENTS; BUSULFAN; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; MIDDLE AGED; MYELOABLATIVE AGONISTS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TACROLIMUS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 84931569621     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.12.016     Document Type: Conference Paper

References (29)

1. M.R. Bishop, R.M. Dean, and S.M. Steinberg Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation Ann Oncol 19 2008 1935 1940
2. R.T. Doocey, C.L. Toze, and J.M. Connors Allogeneic haematopoietic stem-cell transplantation for relapsed and refractory aggressive histology non-Hodgkin lymphoma Br J Haematol 131 2005 223 230
3. A.J. Peniket, M.C. Ruiz de Elvira, and G. Taghipour An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation Bone Marrow Transplant 31 2003 667 678
4. S.W. Kim, T.E. Tanimoto, and N. Hirabayashi Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan Blood 108 2006 382 389
5. K. van Besien, J. Carreras, and P.J. Bierman Unrelated donor hematopoietic cell transplantation for non-Hodgkin lymphoma: long-term outcomes Biol Blood Marrow Transplant 15 2009 554 563
6. M. Hamadani, D.M. Benson Jr., and C.C. Hofmeister Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-Hodgkin lymphomas Biol Blood Marrow Transplant 15 2009 547 553
7. M. de Lima, D. Couriel, and P.F. Thall Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS Blood 104 2004 857 864
8. J. Pidala, J. Kim, and C. Anasetti Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity Bone Marrow Transplant 46 2011 641 649
9. J. Perkins, T. Field, and J. Kim Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes Bone Marrow Transplant 46 2011 1418 1425
10. S. Santarone, J. Pidala, and M. Di Nicola Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with acute lymphoid leukemia Biol Blood Marrow Transplant 17 2011 1505 1511
11. B.D. Cheson, B. Pfistner, and M.E. Juweid Revised response criteria for malignant lymphoma J Clin Oncol 25 2007 579 586
12. M.L. Sorror, M.B. Maris, and R. Storb Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT Blood 106 2005 2912 2919
13. J. Perkins, T. Field, and J. Kim A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis Biol Blood Marrow Transplant 16 2010 937 947
14. J. Pidala, J. Kim, and H. Jim A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation Haematologica 97 2012 1882 1889
15. A.L. Lobashevsky, R.W. Senkbeil, J.E. Townsend, C.A. Mink, and J.M. Thomas Quantitative analysis of chimerism using a short tandem repeat method on a fluorescent automated DNA sequencer Clin Lab Haematol 28 2006 40 49
16. R.J. Jones, K.S. Lee, and W.E. Beschorner Venoocclusive disease of the liver following bone marrow transplantation Transplantation 44 1987 778 783
17. D. Przepiorka, D. Weisdorf, and P. Martin 1994 Consensus Conference on Acute GVHD Grading Bone Marrow Transplant 15 1995 825 828
18. A.H. Filipovich, D. Weisdorf, and S. Pavletic National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: I. Diagnosis and Staging Working Group Report Biol Blood Marrow Transplant 11 2005 945 956
19. R.J. Gray A class of k-sample tests for comparing the cumulative incidence of a competing risk Ann Stat 16 1988 1141 1154
20. J.B. Choudhury Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data Stat Med 21 2002 1129 1144
21. J.B. Perkins, J. Kim, and C. Anasetti Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation Biol Blood Marrow Transplant 18 2012 1099 1107
22. E. Jantunen, and A. Sureda The evolving role of stem cell transplants in lymphomas Biol Blood Marrow Transplant 18 2012 660 673
23. M.L. Sorror, B.E. Storer, D.G. Maloney, B.M. Sandmaier, P.J. Martin, and R. Storb Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia Blood 111 2008 446 452
24. R. Rodriguez, A. Nademanee, and N. Ruel Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma Biol Blood Marrow Transplant 12 2006 1326 1334
25. P. Hari, J. Carreras, and M.J. Zhang Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning Biol Blood Marrow Transplant 14 2008 236 245
26. A.R. Rezvani, B. Storer, and M. Maris Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma J Clin Oncol 26 2008 211 217
27. A.R. Rezvani, L. Norasetthada, and T. Gooley Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience Br J Haematol 143 2008 395 403
28. U. Bacher, E. Klyuchnikov, and J. Le-Rademacher Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood 120 2012 4256 4262
29. B.L. McClune, K.W. Ahn, and H.L. Wang Allotransplantation for patients age ≥ 40 years with non-Hodgkin lymphoma: encouraging progression-free survival Biol Blood Marrow Transplant 20 2014 960 968